Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B
- Registration Number
- NCT02533544
- Lead Sponsor
- Myeong Jun Song
- Brief Summary
This is an open-label, single arm cohort study to see efficacy and safety of tenofovir disoproxil fumarate (TDF) in naïve chronic hepatitis B, retrospectively and prospectively both.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 572
-
Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
-
Adult male and non-pregnant, non-lactating female subjects, 19 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal).
-
Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months)
-
Chronic hepatitis B with the following:
- HBeAg-positive and HBeAb negative at Screening
- Screening HBV DNA ≥ 1x 105 copies/mL
- Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- HBeAg-negative and HBeAb positive at Screening
- Screening HBV DNA ≥ 1x 104 copies/mL
- Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR
- Cirrhosis at Screening
- Screening HBV DNA ≥ 1x 104 copies/mL in HBeAg negative or
- Screening HBV DNA ≥ 1x 105 copies/mL in HBeAg positive
- Screening serum ALT level ≥ ×ULN and ≤ 10 ×ULN (by center laboratory range)
-
A patient who treating with TDF as a treatment-naïve for Hepatitis B. Treatment naïve subjects defined as no history of antiviral therapy or < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir
-
Decompensated liver cirrhosis defined based on a Child-Turcotte-Pugh (CTP) score ≥ 7 (Child B and C) or presence with at least one episode of ascites, jaundice, hepatic encephalopathy or variceal bleeding
-
Any previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit
-
Must be willing and able to comply with all study requirements.
Subjects who meet any of the following exclusion criteria are not to be enrolled in the study.
- Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.
- Co-infection with HCV, HIV
- Evidence of hepatocellular carcinoma (e.g. α-fetoprotein> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure)
- Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible
- Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
- Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion
- Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description tenofovir disoproxil fumarate monotherapy tenofovir disoproxil fumarate a group which treated with tenofovir disoproxil fumarate
- Primary Outcome Measures
Name Time Method The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48 week 48 proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 48
The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96 Week 96 proportion of subjects with plasma HBV DNA levels below 116 copies/mL at Week 96
- Secondary Outcome Measures
Name Time Method The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 The proportion of subjects with plasma HBV DNA levels below 116 copies/mL at every visits
The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96 Week 48 and 96 The proportion of the biochemical (alanine aminotransferase normalization) response of TDF for the treatment of chronic hepatitis B at Week 48 and 96
The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96 Week 48 and 96 The proportion of the serological response (loss of HBeAg and seroconversion to HBeAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96
The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96 Week 48 and 96 The proportion of the serological response (loss of HBsAg and seroconversion to HBsAb) of TDF for the treatment of chronic hepatitis B at Week 48 and 96
The change from baseline in the decline of HBV DNA at every visits week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 The change from baseline in the decline of HBV DNA at every visits
The proportion of patients showing virological breakthrough at week 48 and 96 Week 48 and 96 The proportion of patients showing virological breakthrough at week 48 and 96.
Virological Breakthrough defined as any increase in serum HBV DNA by \>1 log10 from nadir or redetection of serum HBV DNA at levels ≥10-fold the lower limit of detection of the HBV DNA assay after having an undetectable resultThe incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96 Week 48 and 96 The incidence of resistance of TDF among patients showing virological breakthrough at week 48 and 96.
Virological Breakthrough defined as any increase in serum HBV DNA by \>1 log10 from nadir or redetection of serum HBV DNA at levels ≥10-fold the lower limit of detection of the HBV DNA assay after having an undetectable resultThe proportion of improvement of liver function including Child Score, Model for End-stage Liver Disease (MELD) score at Week 48 and 96 Week 48 and 96 The proportion of improvement of liver function including Child Score, MELD score at Week 48 and 96
The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96 Week 48 and 96 The proportion of improvement of Fibrosis marker including Aspartate aminotransferase to Platelet Ratio Index(APRI) at Week 48 and 96
Trial Locations
- Locations (1)
The Catholic University of Korea, Daejeon St.Mary's Hosptial
🇰🇷Junggu, Daejeon, Korea, Republic of
The Catholic University of Korea, Daejeon St.Mary's Hosptial🇰🇷Junggu, Daejeon, Korea, Republic of